Cost breakdown
| Product | Channel | Monthly | Annual |
|---|---|---|---|
| Zepbound 5 mg | Retail cash | $1,086 | $13,032 |
| Zepbound 5 mg vial | Lilly Direct cash-pay | $549 | $6,588 |
| Zepbound 2.5 mg vial | Lilly Direct cash-pay | $399 | $4,788 |
| Zepbound 5 mg vial | Insurance copay | $25-150 | $300-1,800 |
| Compounded tirzepatide | NexLife 12-mo (any dose) | $186 | $2,232 |
| Compounded tirzepatide | Mochi Health | ~$208 | ~$2,496 |
| Compounded tirzepatide | Henry Meds 15 mg | ~$449 | ~$5,388 |
Lilly Direct: cash-pay vial channel
Eli Lilly launched LillyDirect.com in 2024 as a direct-to-patient cash-pay channel for Zepbound vials (not pens). As of May 2026:
- 2.5 mg vial: $399/mo (4 vials)
- 5 mg vial: $549/mo
- 7.5+ mg: prefilled pens only (higher prices)
Lilly Direct reduces the cash-pay cost gap vs compounded, but compounded telehealth (NexLife at $186/mo) remains cheaper at every dose level — especially at 10-15 mg where brand prefilled pens are required.
OSA indication: brand-only
Zepbound was approved December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, based on SURMOUNT-OSA (Malhotra A et al., NEJM 2024). This indication is brand-specific — compounded tirzepatide is used off-label for the same clinical scenario but does not carry the FDA OSA indication.
How to choose
- Brand Zepbound (Lilly Direct vial) if: insurance covers it; you have OSA + obesity and want the FDA-approved indication; you prefer the brand quality signal
- Compounded tirzepatide if: no insurance coverage; want flat-rate pricing through 15 mg; cost-sensitive; comfortable with §503A/§503B regulatory framework